• ACVCACVC
  • DVM 360
  • Fetch DVM 360Fetch DVM 360
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care
By Role
AssociatesOwnersPractice ManagerStudentsTechnicians
Subscriptions
dvm360 Newsletterdvm360 Magazine
News
All News
Association
Breaking News
Education
Equine
FDA
Law & Ethics
Market Trends
Medical
Politics
Products
Recalls
Regulatory
Media
Expert Interviews
The Vet Blast Podcast
Medical World News
Pet Connections
The Dilemma Live
Vet Perspective
Weekly Newscast
dvm360 LIVE!™
Insights
Publications
All Publications
dvm360
Firstline
Supplements
Vetted
Clinical
All Clinical
Anesthesia
Animal Welfare
Behavior
Cardiology
CBD in Pets
Dentistry
Dermatology
Diabetes
Emergency & Critical Care
Endocrinology
Equine Medicine
Exotic Animal Medicine
Feline Medicine
Gastroenterology
Imaging
Infectious Diseases
Integrative Medicine
Nutrition
Oncology
Ophthalmology
Orthopedics
Pain Management
Parasitology
Surgery
Toxicology
Urology & Nephrology
Virtual Care
Business
All Business
Business & Personal Finance
Client Handouts
Hospital Design
Personnel Management
Practice Finances
Practice Operations
Wellbeing & Lifestyle
Continuing Education
Conferences
Conference Coverage
Conference Listing
Conference Proceedings
Resources
CBD in Pets
CE Requirements by State
Contests
Partners
Spotlight Series
Team Meeting in a Box
Toolkit
Vet to Vet
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us

© 2022 MJH Life Sciences and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

By Role
  • Associates
  • Owners
  • Practice Manager
  • Students
  • Technicians
Subscriptions
  • dvm360 Newsletter
  • dvm360 Magazine
  • Contact Us
  • Fetch DVM360 Conference
  • Terms and Conditions
  • Privacy
  • Do Not Sell My Information
  • About Us
  • MJHLS Brand Logo

© 2022 MJH Life Sciences™ and dvm360 | Veterinary News, Veterinarian Insights, Medicine, Pet Care. All rights reserved.

New cancer screening test for dogs now available

December 1, 2020
dvm360 Staff
dvm360, dvm360 January 2020, Volume 51, Issue 1

The simple blood test employs technology that looks for very early nucleosomic markers of cancer in dogs.

Cancer is the most common cause of death in dogs over 2 years of age in the United States,1 with up to half of all dogs over age 10 developing the disease at some point.2 When a cancer diagnosis is suspected, the dog must undergo a variety of costly, time-consuming, and potentially painful diagnostic tests.

Multinational epigenetics company VolitionRx Limited (through its subsidiary Volition Veterinary Diagnostics Development LLC) aims to help veterinarians streamline the cancer diagnostic process with the release of its first product, the Nu.Q Vet Cancer Screening Test. This enzyme-linked immunosorbent assay (ELISA)–based test is noninvasive, inexpensive, and easy to use.

Measuring nucleosomes

When a person or dog has cancer, nucleosomes from the cancer cells are released into the blood and can be measured using antibodies specific to nucleosomes. Nu.Q Vet measures and analyzes the nucleosomes to identify patients that may have cancer. A positive result must then be confirmed by follow-up testing, such as a biopsy or imaging.

In a study of over 330 dogs, the test showed 100% specificity, identifying 74% of lymphomas and 89% of hemangiosarcomas when compared with healthy controls.3,4 These cancer types account for about one-third of all cancers seen in dogs.

Unlike in humans, few routine cancer screening tests are available for animals, said Heather Wilson-Robles, DVM, a professor at Texas A&M University College of Veterinary Medicine & Biomedical Sciences and chief medical officer at Volition Veterinary. “This simple, low-cost blood test can help streamline the diagnostic process and shorten the path to diagnosis thereby allowing treatment (be that therapy or surgery) to be initiated earlier, even before symptoms appear, increasing the chance of the dog’s survival and its quality of life.”

When to use it

Volition’s new product may be used during annual wellness checks in older dogs, in cases of suspected canine cancer, and in younger breeds that are at high risk for the development of cancer, including golden retrievers, boxers, flat-coated retrievers, beagles, Bernese mountain dogs, and others, according to a company press release.

“The launch of the Nu.Q Vet Cancer Screening Test is a stand-out moment in our 10-year history and an extremely important milestone for our company. It demonstrates that our Nu.Q platform has now attained both the reliability and reproducibility to launch in an independent laboratory,” said Cameron Reynolds, chief executive officer of Volition.

Volition’s focus during this initial launch phase will be on driving awareness about the test to veterinary oncologists nationwide as well as to general practice veterinarians in Texas (their Beta market) via social media, direct mail, lunch-and-learns, and a webinar.

US veterinarians can order the Nu.Q Vet Cancer Screening Test from the GI Lab at Texas A&M University College of Veterinary Medicine & Biomedical Sciences. The cost is $122 per test.

Interested in learning more? Click here or register for this webinar hosted by Wilson-Robles and Sue Ettinger, DVM, DACVIM (Oncology), on December 9 at 7 pm CT.


References

  1. 1. Fleming JM, Creevy KE, Promislow DE. Mortality in North American dogs from 1984 to 2004: an investigation into age-, size-, and breed-related causes of death. J Vet Intern Med. 2011;25(2):187-198. doi:10.1111/j.1939-1676.2011.0695.x
  2. 2. Davis BW, Ostrander EA. Domestic dogs and cancer research: a breed-based genomics approach. ILAR J. 2014;55(1):59-68. doi:10.1093/ilar/ilu0173.
  3. 3. Dolan C, Wilson-Robles H, Miller T, et al. Characterizing circulating nucleosomes in the plasma of dogs with lymphoma. Presented at the 2020 Veterinary Cancer Society Virtual Conference. October 15-17.
  4. 4. Wilson-Robles H, Miller T, Jarvis J, et al. Characterizing circulating nucleosomes in the plasma of dogs with hemangiosarcoma. Presented at the 2020 Veterinary Cancer Society Virtual Conference. October 15-17.
download issueDownload Issue: dvm360 January 2020

Related Content:

MedicalClinicalOncologyBreaking NewsAssociatesTechniciansRolesdvm360 January 2020
Animal pain management: where have we been and where are we going?
Animal pain management: where have we been and where are we going?
3 Must-reads for veterinary oncology: part 2
3 Must-reads for veterinary oncology: part 2
Wellness Pet Company debuts new brand of natural dog treats
Wellness Pet Company debuts new brand of natural dog treats

Latest News

Animal pain management: where have we been and where are we going?

ACANA hairball control food receives FDA approval

Wellness Pet Company debuts new brand of natural dog treats

Louisville Zoo welcomes baby zebra

View More Latest News